Cytation 9 multimode reader or equal instrument

This is a combined synopsis/solicitation for commercial products or commercial services prepared in accordance with FAR RFO part 12. This announcement constitutes the only solicitation. Offers are being requested and a separate written solicitation will not be issued. The solicitation number is 75F40126Q134405. This solicitation is issued as a Request for Quote (RFQ) for cytation 9 multimode reader or equal instrument. This acquisition is not set-aside for small business concerns. This solicitation incorporates provisions and clauses by reference. The full text of provisions and clauses may be accessed electronically at https://www.acquisition.gov/far-overhaul. The associated North American Industry Classification System (NAICS) Code is- 334516 - Analytical Laboratory Instrument Manufacturing; the applicable Small Business Size Standard is 1,000 employees. This requirement is solicited as unrestricted full and open competition, any sized business may submit a quote. Schedule of Items (all shipping and handling shall be included in the price) Item Description Est. QTY Unit of Measure Unit Price Extended Price 1 Cytation 9 Multimode Reader, or equivalent, as specified herein 1 Ea $___________ $___________ Grand Total: $ ________________________ Statement of Work: Plate Reader Part I: General Information A. Introduction The Laboratory of Mucosal Pathogens and Cellular Immunology (LMPCI) requires a multimode plate reader to support a wide range of bacterial assays. The LMPCI has found equipment that meets their needs; the BioTek Cytation 9 (or the equivalent) system is designed for time-resolved measurement of labeled or unlabeled microbes using any combination of visible light, fluorescence, or luminescence in a range of microplate formats, and is upgradeable in future to add microscopy for biofilm imaging. B. Background The Laboratory of Mucosal Pathogens and Cellular Immunology (LMPCI) conducts original research that informs the development and regulation of multiple biologic products related to: a) bacteriophage therapy as an alternative treatment for bacterial infection because of an increase in antibiotic-resistant bacteria; b) live biotherapeutic products for the treatment of a wide range of acute and chronic diseases; and c) the prevention and treatment of pertussis infections. All of these projects include experiments in which we use absorbance, fluorescence, and/or luminescence to answer key questions about the growth and responses of bacteria to certain stimuli or genetic changes. The laboratory needs to replace a BioTek Cytation 3 multimode plate 75F40126Q134405 1 of 14 -- 1 of 14 -- reader that has reached end-of-life. This unit also supported research activities by multiple Laboratories in the Division of Bacterial, Parasitic, and Allergenic Products, in addition to LMPCI. The most up-to-date replacement for the end-of-life Cytation 3 unit is the Cytation 9. The currently available Cytation 7 will be retired by the manufacturer later this year, therefore the Cytation 9 is the replacement instrument that will offer the longest usable life while also having our required capabilities. C. Scope A new BioTek multimode plate reader or the equivalent to replace our current Cytation 3 unit, which has reached end-of-life. Part II: Work Requirements A. Technical Requirements The plate reader shall have the following: • Variable bandwidth monochromator-based detection modes including UV-Vis absorbance, fluorescence, luminescence. • Absorbance readings of 230-999 nm with a dynamic range between 0 – 4.0 OD, an absorbance resolution of 0.001 OD, and pathlength correction. • Ability to conduct direct nucleic acid quantification in microvolume (2 μL) samples. • Fluorescence excitation/emission wavelength range of 250-700 nm (by monochromators), with bandwidth in 1 nm increments. • Luminescence detection range of 300-700 nm. • For absorbance and fluorescence detection modes, a reading speed of less than 30 seconds per plate. • Reagent injector able to dispense 5-1000 μL of at least two reagents, in 1 μL increments. • The capability to hold and read standard microtiter plates ranging from 6-well to 384-well formats. • The ability to control and read endpoint and kinetic assay studies. • An orbital shaking mechanism capable of linear, orbital, and double orbital shaking that ensures cells will not settle during long term kinetic assays. • Consistent and reliable temperature control up to 65°C, plus the ability to set a temperature gradient from the top to the bottom of the wells to prevent condensation on the sealed plates (four-zone incubation with condensation control). • A 24 VDC power supply compatible with 100-240 volts AC. • An easy-to-use program/app interface that provides instrument control, data collection, and analysis. Specifically, the instrument should be compatible with Gen5 software to enable compatibility with existing datasets and lab instrumentation. • Upgradeable to include automated, timelapse, color brightfield and fluorescence microscopic imaging of microtiter plates and hemocytometers, with magnification up to at least 60X objective and z-projection image processing. B. Deliverables A new Cytation 9 or the equivalent multimode microtiter plate reader which meets all the above technical requirements. 75F40126Q134405 2 of 14 -- 2 of 14 -- Additional System Requirements: 1. The components and equipment shall be newly manufactured, not used or refurbished, or previously used for demonstration. 2. Offered systems shall be a turn-key solution i.e., the Contractor shall be responsible for providing all hardware, components, instruments, software, and that otherwise required to meet these specifications and the FDA’s stated need. 3. Systems/equipment shall be warranted for not less than one (1) year from FDA acceptance of the system(s), to include on-site training. Warranty shall be included with the equipment and not separately priced. Warranty services shall includ…